Kerecis

Kerecis is pioneering the use of intact fish skin in the globally expanding cellular-therapy and regenerative-medicine markets. Intellectual Property Kerecis has been awarded multiple patents protecting the core technology in the U.S. Kerecis is committed to building a substantial patent portfolio protecting the company´s intellectual property. Kerecis is pioneering the use of fish skin and fatty acids in the globally expanding cellular therapy. Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, today announced the availability of Shield Standard, which combines a fish-skin graft and silicone backing for efficient. The intact Kerecis fish skin is being used to treat wounds, burns and other complex acute and chronic wounds including diabetic, venous, trauma, and surgical wounds. Because no known viral transfer risk exists between North-Atlantic Cod and humans, the Kerecis patented fish skin is only gently processed and retains its similarity to human skin. Most skin substitutes products are based on tissues of human and porcine origin.